Search results for "programmed cell death ligand 1"

showing 1 items of 1 documents

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1

2018

Immunomodulatory drugs and monoclonal antibody-based immunotherapies have significantly improved the prognosis of the patients with multiple myeloma (MM) in the recent years. These new classes of reagents target malignant plasma cells (PCs) and further modulate the immune microenvironment, which prolongs anti-MM responses and may prevent tumor occurrence. Since MM remains an incurable cancer for most patients, there continues to be a need to identify new tumor target molecules and investigate alternative cellular approaches using gene therapeutic strategies and novel treatment mechanisms. Osteoclasts (OCs), as critical multi-nucleated large cells responsible for bone destruction in >80% …

lcsh:Immunologic diseases. Allergy0301 basic medicineCarcinogenesisAngiogenesismedicine.medical_treatmentOsteoimmunologyT cellPlasma CellsProgrammed Cell Death 1 ReceptorImmunologyOsteoclastsCell CommunicationReviewB7-H1 AntigenImmune tolerance03 medical and health sciencesImmune systemAntigens NeoplasmImmune ToleranceTumor MicroenvironmentmedicineAnimalsHumansImmunology and AllergyBone ResorptionImmunologic Surveillancebone marrow microenvironmentTumor microenvironmentbusiness.industryprogrammed cell death ligand 1Immunotherapymultiple myeloma030104 developmental biologymedicine.anatomical_structureprogrammed cell death 1osteoclastosteoblastCancer researchimmunotherapylcsh:RC581-607businessB7-H1 AntigenSignal TransductionFrontiers in Immunology
researchProduct